This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Disodium etidronate in Paget's disease

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Disodium etidronate was the first bisphosphonate to be used clinically in the management of Paget's disease.

Adverse effects include:

  • nausea
  • diarrhoea
  • in 5% of patients there may be an increase in bone pain during the first four weeks or so of treatment
  • at higher doses there is an increased incidence of spontaneous fractures because of demineralization that occurs with high doses

There have now been developed second- and third- generation bisphosphonates.

The summary of product characteristics should be consulted before prescribing this drug.

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.